GlassScriptPhysician profile
Linda M Bott
NPI 1134423304
$848.60
in general payments reported to CMS, 2019-2025
14 companies · $84.69 in 2025
The $84.69 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2022: $221 · 2023: $168 · 2024: $163 · 2025: $84.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $254.41 | 2021-2025 | |
| Lilly USA, LLC | $171.63 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $98.93 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $61.67 | 2021-2022 | |
| Novo Nordisk INC | $57.17 | 2022-2024 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $50.56 | 2021-2023 | Yupelri |
| Pfizer INC. | $41.54 | 2024-2025 | |
| Abbott Laboratories | $22.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.27 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.71 | 2022 | |
| Amarin Pharma, INC. | $15.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.95 | 2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $13.74 | 2022 | |
| Genentech USA, INC. | $8.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Bott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.